HROW·Nasdaq·US
Harrow
Harrow is a U.S.-based ophthalmic pharmaceutical company focused on the development, commercialization, and distribution of prescription eye-care therapies. Its revenue is driven primarily by branded ophthalmic products and compounded medications sold to eye-care professionals and patients.
Recent Activity
Updated Oct 10, 2026
–Harrow closed its acquisition of TYRVAYA, the first and only FDA-approved nasal spray for dry eye disease.
–The acquisition adds a differentiated, drop-free treatment option to Harrow's ocular surface franchise.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.